Abstract
Gene therapy, the transfer of genetic material for therapeutic purposes, has undergone an explosive development in the last few years. Within this context, development of gene therapy approaches for the neuroendocrine system, while incipient, has already generated a core of results which emerge as a promising area of research in neuroendocrinology. The present review presents a brief description of the viral vector-based gene delivery systems being currently used in neuroendocrinology, namely the adenoviral and herpes simplex type-1 (HSV-1)-derived vector systems, as well as an updated account of neuroendocrine pathologies for which gene therapy approaches in animal models are being implemented is provided. Current research efforts include treatment of experimental pituitary tumors by adenoviral vector-mediated transfer of the suicide gene for the HSV-1 thymidine kinase, which converts the prodrug ganciclovir into a toxic metabolite. An adenoviral vector encoding the human retinoblastoma suppressor oncogene has also been successfully used to rescue the phenotype of spontaneous pituitary tumors of the pars intermedia in mice. At the hypothalamic level, an adenovirus harboring the cDNA for arginine vasopressin has been used in Brattleboro rats to correct diabetes insipidus for several weeks. The last part of the review outlines the potential of gene therapy to correct age-associated neurodegenerative processes at the neuroendocrine level. Although effective implementation of gene therapy strategies still faces significant technical obstacles, these are likely to be progressively overcome as gene delivery systems are being improved.
References
1.
Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320–1323.
2.
Hidaka C, Milano E, Leopold PL, Bergelson JM, Hackett NR, Finberg RW, Wickham TJ, Kovesdi I, Roelvink P, Crystal RG: CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblast. J Clin Invest 1999;103:579–587.
3.
Hitt M, Bett AJ, Addison CL, Prevec L, Graham FL: Techniques for human adenovirus vector construction and characterization. Meth Mol Gen 1995;7:13–30.
4.
Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM: Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91:4407–4411.
5.
Park JS, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL: A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996;93:13565–13570.
6.
Parks RJ, Graham FL: A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol 1997;71:3293–3298.
7.
Ideguchi M, Kajiwara K, Yoshikawa K, Uchida T, Iho H: Local adenovirus-mediated CTLA4-immunoglobulin expression suppresses the immune responses to adenovirus vectors in the brain. Neuroscience 2000;95:217–226.
8.
Geddes BJ, Harding TC, Hughes DS, Byrnes AP, Lightman SL, Conde G, Uney JB: Persistent transgene expression in the hypothalamus following stereotaxic delivery of a recombinant adenovirus: Suppression of the immune response with cyclosporin. Endocrinology 1996;137:5166–5169.
9.
Ilan Y, Prakash R, Davidson A, Jona V, Droguett G, Horwitz MS, Roy Chowdhury N, Roy Chowdhury J: Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors. J Clin Invest 1997;99:1098–1106.
10.
Roizman B: The function of herpes simplex virus genes. A primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA 1996;93:11307–11312.
11.
Wolfe D, Goins WF, Yamada M, Moriuchi S, Krisky DM, Oligino TJ, Marconi PC, Fink DJ, Glorioso JC: Engineering Herpes Simplex virus vectors for CNS applications. Exp Neurol 1999;159:34–46.
12.
Tomasec P, Bain D, Castro MG, Preston CM, Lowenstein PR: Herpes simplex virus temperature-sensitive mutant tsK as a vector for neuronal gene transfer; in Lowenstein PR, Enquist LW (eds): Protocols for Gene Transfer in Neuroscience: Towards Gene Therapy of Neurological Disorders. Chichester, Wiley, 1996, pp 169–186.
13.
Daniels GH, Martin JB: Neuroendocrine regulation and diseases of the anterior pituitary and hypothalamus; in Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (eds): Harrison’s Principles of Internal Medicine. New York, McGraw-Hill, 1995, pp 1891–1918.
14.
Shimon I, Melmed S: Management of pituitary tumors. Ann Intern Med 1998;129:472–483.
15.
Melmed S: General aspects of the management of pituitary tumors by surgery or radiation therapy; in DeGroot LJ (ed): Endocrinology. Philadelphia, Saunders, 1997, pp 497–503.
16.
Bevan JS, Webster J, Burke CW, Scanlon MF: Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:220–240.
17.
Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemia amenorrhea. N Engl J Med 1994;331:904–909.
18.
Sheppard MC: Aims of treatment and definition of cure; in Wass JAH (ed): Treating Acromegaly – 100 Years On. Bristol, Society for Endocrinology, 1994, pp 17–31.
19.
Castro MG, Goya RG, Sosa YE, Rowe J, Larregina AT, Morelli AE, Lowenstein PR: Expression of transgenes in normal and neoplastic anterior pituitary cells using recombinant adenoviruses: Long-term expression, cell cycle dependency, and effects on hormone secretion. Endocrinology 1997;138:2184–2194.
20.
Goya RG, Rowe J, Sosa YE, Tomasec P, Lowenstein PR, Castro MG: Use of recombinant herpes simplex virus type I vectors for gene transfer into tumour and normal anterior pituitary cells. Mol Cell Endocrinol 1998;139:199–207.
21.
Windeatt S, Southgate TD, Dewey RA, Bolognani F, Perone MJ, Larregina AT, Maleniak TC, Morris ID, Goya RG, Klatzmann D, Lowenstein PR, Castro MG: Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas. J Clin Endocrinol Metab 2000;85:1296–1305.
22.
Lee EJ, Anderson LM, Thimmapaya B, Jameson JL: Targeted expression of toxic genes directed by pituitary hormone promoters: A potential strategy for adenovirus-mediated gene therapy of pituitary tumors. J Clin Endocrinol Metab 1999;84:786–794.
23.
Southgate TD, Windeatt S, Smith-Arica J, Gerdes CA, Perone MJ, Morris I, Davis JR, Klatzmann D, Lowenstein PR, Castro MG: Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vectors in vitro and in vivo in normal and estrogen/sulpiride-induced hyperplastic anterior pituitaries. Endocrinology 2000;141:3493–3505.
24.
Lee EJ, Thimmapaya B, Jameson JL: Stereotactic injection of adenoviral vectors that target gene expression to specific pituitary cell types: Implications for gene therapy. Neurosurgery 2000;46:1461–1469.
25.
Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH, Lee EY: Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 1994;9:1021–1029.
26.
Riley DJ, Yu A, Lee W-H: Adenovirus-mediated retinoblastoma gene therapy supresses spontaneous pituitary melanotroph tumors in Rb+/– mice. Nat Med 1996;2:1316–1321.
27.
Freese A, During MJ, Davidson BL, Gennarelli TA, Kaplitt MG, Flamm ES, Snyder PJ: Transfection of human lactotroph adenoma cells with an adenovirus vector expressing tyrosine hydroxylase decreases prolactin release. J Clin Endocrinol Metab 1996;81:2401–2404.
28.
Senut MC, Aubert I, Horner PJ, Gage FH: Gene transfer for adult CNS regeneration and aging; in Chiocca EA, Breakefield XO (eds): Gene Therapy for Neurological Disorders and Brain Tumors. Totowa, Humana Press, 1998, pp 345–375.
29.
Valtin H: Genetic models of diabetes insipidus; in Windhager EE (ed): Handbook of Physiology. New York, Oxford University Press, 1992, pp 1281–1316.
30.
Geddes BJ, Harding TC, Lightman SL, Uney JB: Long-term gene therapy in the CNS: Reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin. Nat Med 1997;3:1402–1404.
31.
Vasquez EC, Beltz TG, Meyrelles SS, Johnson AK: Adenovirus mediated gene delivery to hypothalamic magnocellular neurons in mice. Hypertension 1999;21:756–761.
32.
Tomasec P, Preston CM, Linton EA, Ahmed I, Lowenstein PR, Castro MG: Generation of a recombinant herpes simplex virus type 1 expressing the rat corticotropin-releasing hormone precursor: Endoproteolytic processing, intracellular targeting and biological activity. Neuroendocrinology 1999;70:439–450.
33.
Hornykiewics O, Kish S: Biochemical pathology of Parkinson’s disease. Adv Neurol 1986;45:19–34.
34.
Sarkar DK, Gottschall PE, Meites J: Damage to hypothalamic dopaminergic neurons is associated with development of prolactin-secreting pituitary tumors. Science 1982;218:684–686.
35.
Goya RG, Lu JKH, Meites J: Gonadal function and pituitary and mammary pathology in the aging rat. Mech Age Dev 1990;56:77–88.
36.
Cónsole G, Gómez Dumm CL, Brown OA, Ferese C, Goya RG: Sexual dimorphism in the age changes of pituitary lactotrophs in rats. Mech Age Dev 1997;95:157–166.
37.
Lawton F, Mac Dermott J: Abnormal regulation of prolactin release in idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1980;43:1012–1015.
38.
Lin JY, Mai LM, Pan JT: Effects of systemic administration of 6-hydroxydopamine, 6-hydroxydopa and 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine (MPTP) on tuberoinfundibular dopaminergic neurons in the rat. Brain Res 1993;624:126–130.
39.
Connor B, Dragunow M: The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Rev 1998;27:1–39.
40.
Lin, LFH, Doherty DH, Lile JD, Bektes S, Collins F: GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130–1132.
41.
Tomac A, Lindqvist E, Lin LFH, Ögrenn SO, Young D, Hoffer BJ, Olson L: Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995;373:335–339.
42.
Choi-Lundberg DL, Lin Q, Chang YN, Chiang YL, Hay CM, Mohajeri H, Davidson BL, Bohn MC: Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997;275:838–841.
43.
Mandel RJ, Spratt SK, Snyder RO, Leff SE: Midbrain injection of recombinant adeno-associated virus encoding rat glial cell-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson’s disease in rats. PNAS 1997;94:14083–14088.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
